chevron_leftBack
As of 24 April 2025, H. Lundbeck A/S has a market cap of $4.32B USD, ranking #3170 globally and #23 in Denmark. It ranks #273 in the Healthcare sector, and #44 in the Drug Manufacturers - Specialty & Generic industry.
Key Stats
Market Cap
$4.32BUSD
28.37B DKK
Enterprise Value
$6.16BUSD
40.4B DKK
Revenue (TTM)
$3.35BUSD
22.0B DKK
EBITDA (TTM)
$941.1MUSD
6.17B DKK
Net Income (TTM)
$479.09MUSD
3.14B DKK
EBITDA Margin
28%
Profit Margin
14%
PE Ratio
9.0
Company Profile
Country (HQ)
Sector
Healthcare
CEO
Charl van Zyl
open_in_new
Employees
5,707
Founded
1915
Website
lundbeck.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 6.8% | 3.5% | -24% | -23% | -35% | -11% |
Upcoming Earnings
Earnings Date
Wed, May 14
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
HLUN-A
H. Lundbeck A/S Class A
ISIN: DK0061804697
Shares Out.:
Shares Outstanding:
198.799M1
Shares Float:
39.76M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
25.05 DKK | |
|
HLUN-B
H. Lundbeck A/S Ordinary Shares - Class B
ISIN: DK0061804770
Shares Out.:
Shares Outstanding:
792.428M1
Shares Float:
269.41M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
29.36 DKK | |
|
0ABR
H. Lundbeck A/S Class A
ISIN: DK0061804697
|
25.10 DKK | |
|
0ND5
H. Lundbeck A/S Ordinary Shares - Class B
ISIN: DK0061804770
Shares Out.:
Shares Outstanding:
792.428M1
Shares Float:
269.41M2
|
28.56 DKK | |
|
HLBBF
H. Lundbeck A/S Ordinary Shares - Class B
ISIN: DK0061804770
Shares Out.:
Shares Outstanding:
792.428M1
Shares Float:
269.41M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
4.42 USD | |
|
HLUBF
H. Lundbeck A/S Class A
ISIN: DK0061804697
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
3.70 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About H. Lundbeck A/S
H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression. It also provides Northera for symptomatic neurogenic orthostatic hypotension; Onfi for epilepsy; Sabril for refractory complex partial seizures and infantile spasms; Ebixa for dementia, Azilect for Parkinson’s disease; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol for psychosis. In addition, the company develops Eptinezumab for migraine prevention; Eptinezumab, which is in phase 3 clinical trial for cluster headache; Lu AG09222, which is in phase 2 clinical trial for migraine prevention; Lu AG13909 that is in phase 1 clinical trial for neurohormonal dysfunctions; Brexpiprazole for post-traumatic stress disorder; Lu AF28996, which is in phase 1 clinical trial for Parkinson’s disease; MAGLi program that is in phase 1 clinical trial for neurology; Bexicaserin, which is in phase 3 clinical trial for developmental and epileptic encephalopathies; Amlenetug that is in phase 3 clinical trial for synucleinopathies; and Lu AG22515, which is in clinical phase 1 clinical trial for neurology. The company was founded in 1915 and is headquartered in Valby, Denmark.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
Country |
|---|---|---|
Stenocare A/S
CPH: STENO
|
$944.12K
-100%
6.19M DKK
|
